Drug Type Bispecific antibody |
Synonyms Dilpacimab (USAN/INN), Immunoglobulin, anti-(notch ligand dll4/vascular endothelial growth factor) (synthetic human pr-1283233 heavy chain), disulfide with synthetic human pr-1283233 light chain, dimer, ABT-165 + [1] |
Target |
Mechanism DLL4 inhibitors(Delta-like protein 4 inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | US | 20 Mar 2018 | |
Metastatic Colorectal Carcinoma | Phase 2 | BE | 20 Mar 2018 | |
Metastatic Colorectal Carcinoma | Phase 2 | CA | 20 Mar 2018 | |
Metastatic Colorectal Carcinoma | Phase 2 | KR | 20 Mar 2018 | |
Metastatic Colorectal Carcinoma | Phase 2 | ES | 20 Mar 2018 | |
Metastatic Colorectal Carcinoma | Phase 2 | TW | 20 Mar 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 08 Aug 2013 |
Phase 1 | 55 | twztabhzgy(nxocorover) = cmdrspwsof mhmvbwpdzj (vynxmgmyus ) View more | Positive | 01 Oct 2021 | |||
Phase 1 | 16 | ABT-165 2.5 mg/kg plus FOLFIRI | ukgkqczljw(xrnorhkphu) = olrlotalur oljwtajsdn (nakyflvdyo ) View more | Positive | 20 Jun 2018 | ||
Phase 1 | 54 | hjbhwfozld(klgsjxybmx) = Other AEs of interest with respect to mechanism of action included ... gastrointestinal perforation (GIP) (3.7%) rzqguscazf (xejnvhiqax ) View more | Positive | 20 May 2016 |